SCHEDULE 13G: S.H.N. Financial Investments Discloses 9.99% Stake in Hepion Pharmaceuticals

S.H.N. Financial Investments Ltd. has reported a 9.99% beneficial ownership stake in Hepion Pharmaceuticals, Inc., including shares acquired through a recent offering.

Summary

• S.H.N. Financial Investments Ltd. has filed a Schedule 13G, disclosing its beneficial ownership in Hepion Pharmaceuticals, Inc.
• The reporting person beneficially owns 1,060,883 shares of Hepion Pharmaceuticals' Common Stock.
• This ownership represents 9.99% of the company's outstanding Common Stock.
• The stake includes 231,849 previously held shares and 829,034 shares purchased in a recent offering.
• S.H.N. Financial Investments also acquired 4,709,428 Pre-Funded Warrants, 5,538,462 Series A Warrants, and 5,538,462 Series B Warrants, all subject to a 9.99% beneficial ownership limitation.
• The percentage calculation is based on 10,619,458 shares of Common Stock outstanding immediately after the offering, as per the Issuer's Prospectus filed on January 23, 2025.
• Nir Shamir, CEO of S.H.N. Financial Investments, may be deemed to beneficially own these securities but disclaims beneficial ownership for all other purposes.

Sentiment

Score: 7

Explanation: The document is a factual disclosure of a significant institutional investment. The acquisition of a near 10% stake by an institutional investor is generally a positive signal, indicating confidence in the company, although the filing itself is neutral in tone.

Positives

• A significant institutional investor, S.H.N. Financial Investments Ltd., has taken a substantial 9.99% stake in Hepion Pharmaceuticals, potentially signaling confidence in the company.
• The acquisition of shares through a recent offering indicates participation in the company's capital raising efforts.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding Hepion Pharmaceuticals' future operations or financial performance, focusing solely on the beneficial ownership stake.

Management Comments

• "Nir Shamir is the Chief Executive Officer of SHN. As such, SHN and Mr. Shamir may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities described herein."
• "To the extent Mr. Shamir is deemed to beneficially own such securities, Mr. Shamir disclaims beneficial ownership of these securities for all other purposes."

Industry Context

This filing indicates an institutional investor's increased stake in a pharmaceutical company, which is a common occurrence in the biotech and pharma sectors where strategic investments can signal confidence in a company's drug pipeline or market potential. Such investments can also be part of broader portfolio diversification strategies by financial institutions.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a near 10% stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: The investment provides capital to the company (implied by the 'offering' participation) and signals external validation of its prospects.

Key Dates

Keywords

Hepion Pharmaceuticals, S.H.N. Financial Investments, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, equity offering, pharmaceuticals